$SLN

$19.78 +$0.11 (0.56%) Close

$SLN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 141.7M shares outstanding

Who owns SLN?

By type of holder

Institutions 15.6% Insiders 0.0% Everyone else 84.4%

Concentration Top 10 holders own 20.3%

Richard Griffiths 10.2% · Siren, L.L.C. 2.3%

Institutional ownership

15.6%

+1.5 pts vs last qtr

Institutional holders

+15 vs last qtr

Net shares bought

+2.1M

by institutions in Q2 2026

New / sold out

20 / 5

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Soleus Capital Management, L.P. NEW +630.0K
Balyasny Asset Management L.P. NEW +611.0K

Biggest sellers in Q2 2026

Nantahala Capital Management, LLC −800.0K
Great Point Partners LLC −570.5K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Silence Therapeutics PLC in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2022–FY2025

+46.7%

+13.63% a year

Each share's claim on the business

−31.8%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $53.3M

over 4 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years2% 3–5 years16% 1–3 years52% Under 1 year30%

Quarterly turnover

19.0%

of institutional shares changed hands

Top 10 managers, median time held

1.8 years

Super Investors

Investment managers reporting SLN on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
SL Siren, L.L.C.	3.3M	2.34%	+400.0K (+13.7%)	2024	0.7%
Shares held by quarter Peak holding3.3M (Q2'26) Change over 8 quarters+479.7K Share of the company2.340% Siren, L.L.C.'s full portfolio →
TC TCG Crossover Management, LLC	3.0M	2.14%	Unchanged	2022	0.8%
Shares held by quarter Peak holding3.0M (Q3'24) Change over 8 quarters0 Share of the company2.140% TCG Crossover Management, LLC's full portfolio →

Siren, L.L.C.

3.3M

% of company

2.34%

Change vs last qtr

+400.0K (+13.7%)

Held since

2024

TCG Crossover Management, LLC

3.0M

% of company

2.14%

Change vs last qtr

Unchanged

Held since

2022

28 more super investors behind a free account

See every manager holding Silence Therapeutics PLC, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting SLN on Form N-PORT; together they hold 0.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FA Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII	$5.06M	482.1K	0.34%	0.23%	July 31, 2026
IB iShares Biotechnology ETF iShares Trust	$2.04M	185.8K	0.13%	0.02%	June 30, 2026

Fidelity Advisor Biotechnology Fund

Fidelity Advisor Series VII

Position value

$5.06M

% of company

0.34%

% of the fund

0.23%

As of

July 31, 2026

iShares Biotechnology ETF

iShares Trust

Position value

$2.04M

% of company

0.13%

% of the fund

0.02%

As of

June 30, 2026

10 more funds behind a free account

See every fund holding Silence Therapeutics PLC and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
RG Richard Griffiths 5%+ holder 13D · 8.0%	14.4M	10.15%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company10.150% Disclosed stake13D · 8.0% View the 13D/G filing →

Richard Griffiths

5%+ holder13D · 8.0%

14.4M

% of company

10.15%

Change vs last qtr

—

Held since

—

Comments